At Cellebration, we have mastered the technology for isolating the maximum number of viable stem cells from either the autologous sources of your body or allogenic with a matched donor to treat cardiovascular disease.
Stem cell treatment involves administration of concentrated cells in the targeted area, wherein they can colonize in the damaged area, adapt the properties of resident stem cells, and initiate some of the lost functions that have been compromised by the disease or injury.
Research data suggests that the differentiation of stem cells into cardiomyogenic lineage are known to express angiogenic properties thereby increasing the network of blood vessels, maximizing the flow of blood, and improving heart efficiency.
The mesenchymal stem cells isolated from both allogenic and autologous sources are known to differentiate into myogenic lineage, thus improving the cardiac pumping. These cells are administered through one of two methods after a considerably analysis of each patient’s unique history.
Local Administration
In this delivery mode, cells are infused into the peripheral veins to expand blood volumes in the system, to ensure that the maximum number of cells are reaching the targeted area.
Intravenous Administration
In this delivery mode, cells are infused into the peripheral veins to expand blood volumes in the system, to ensure that the maximum number of cells are reaching the targeted area.
Once infused back in the body, these cells can be repopulated at the damaged parts of the cardiovascular system. Through strong paracrine effects, they differentiate into lost or damaged heart cells, and muscles and create new blood vessels to improve the supply of blood or help in production of supporting cells to improve the functioning of the cardiovascular system. Thus, with our standardized, broad based and holistic approach, it is now possible to obtain noticeable improvements in the patients with heart diseases, for symptoms as well as their functional abilities.